Liminatus Pharma, Inc. 8-K

What Happened
Liminatus Pharma, Inc. (LIMN) announced on an 8-K that it received a notice from the Nasdaq Listing Qualifications Department on January 15, 2026, stating the company is not in compliance with Nasdaq Listing Rule 5450(a)(1) (the $1 bid-price rule) based on the closing bid price over the last 30 consecutive business days. The notice does not affect the immediate listing status; LIMN common stock will continue trading on Nasdaq under the symbol "LIMN" while the company pursues remedies.

Key Details

• Notice received: January 15, 2026 (Nasdaq deficiency notice for bid-price noncompliance).
• Compliance period: 180 calendar days to regain compliance — deadline July 14, 2026.
• Cure methods: Regain a closing bid price of at least $1 for 10 consecutive business days, or implement a reverse stock split (must be completed no later than 10 business days before the compliance period ends).
• Trading status: No immediate delisting; shares continue to trade on Nasdaq. Company may request additional time if it fails to regain compliance in the initial period.

Why It Matters
For investors, the notice signals a risk that LIMN could face delisting from Nasdaq if it does not remedy the low share price within the prescribed timeframe. Continued noncompliance can reduce liquidity, affect institutional interest, and lead to additional corporate actions (such as a reverse stock split) that would change the share count. The company stated it is working to regain compliance but warned there is no assurance it will succeed.